Candriam S.C.A. Has $14.68 Million Position in IDEXX Laboratories, Inc. $IDXX

Candriam S.C.A. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 70.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,975 shares of the company’s stock after selling 56,053 shares during the period. Candriam S.C.A.’s holdings in IDEXX Laboratories were worth $14,678,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. Empowered Funds LLC raised its holdings in shares of IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories in the second quarter valued at $265,000. Ameritas Advisory Services LLC acquired a new position in IDEXX Laboratories during the second quarter worth $36,000. Callan Family Office LLC raised its stake in IDEXX Laboratories by 354.5% during the second quarter. Callan Family Office LLC now owns 2,486 shares of the company’s stock worth $1,333,000 after acquiring an additional 1,939 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of IDEXX Laboratories by 14.2% during the second quarter. Blue Trust Inc. now owns 177 shares of the company’s stock valued at $95,000 after acquiring an additional 22 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $639.79 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm’s 50 day moving average is $691.95 and its 200-day moving average is $666.49. The firm has a market capitalization of $51.09 billion, a price-to-earnings ratio of 48.95, a PEG ratio of 3.93 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Morgan Stanley boosted their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.